What is INTS's current stock price?

INTS (Intensity Therapeutics, Inc.) is currently trading at $4.71 with a market cap of $8.9M.

What sector is Intensity Therapeutics, Inc. in?

Intensity Therapeutics, Inc. (INTS) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is INTS a good stock to buy?

Analysts have a Buy consensus on INTS with a price target of $125.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

INTS Intensity Therapeutics, Inc.

Healthcare

$4.71+1.07%ClosedMarket Cap: $8.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

11.96

P/S

0.00

EV/EBITDA

0.15

DCF Value

$0.83

FCF Yield

-102.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-136.8%

ROA

-87.0%

ROIC

-110.1%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-2.4M	$—
Q4 null	$0.00	$-3.1M	$—
FY null	$0.00	$-11.6M	$—
Q3 null	$0.00	$-2.7M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$125.00

Target (Median)

$125.00

Target Range

$125.00 - $125.00

0 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

BenchmarkSpeculative Buy

2025-08-20

Brookline CapitalBuy

2025-08-12

Trading Activity

Insider Trades

View All

BENDER LEWIS Hdirector, officer: President and CEO

SellMon Mar 30

Wesolowski John Mofficer: Principal Accounting Officer

SellMon Jan 05

Talamo Josephofficer: Chief Financial Officer

SellMon Jan 05

Wesolowski John Mofficer: Principal Accounting Officer

SellWed Jul 02

Talamo Josephofficer: Chief Financial Officer

SellWed Jul 02

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

3.26

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Peers